To include your compound in the COVID-19 Resource Center, submit it here.

2Q approvals

2Q approvals

Company Approvals
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Japan approves Soliris eculizumab to treat paroxysmal nocturnal hemoglobinuria (PNH)
Amgen Inc. (NASDAQ:AMGN) FDA approves Prolia denosumab to treat osteoporosis in postmenopausal women whoare at high risk of fractures or have failed or are intolerant to other osteoporosis therapy; EC approves Prolia to treat osteoporosis in postmenopausal women and to treat bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures
BioAlliance Pharma S.A. (Euronext:BIO) FDA approves Oravig miconazole to treat oropharyngeal candidiasis
Celgene Corp. (NASDAQ:CELG) Japan approves Revlimid lenalidomide in combination with dexamethasone to treat relapsed or refractory multiple myeloma (MM)
Cipher Pharmaceuticals Inc. (TSX:DND) FDA approves Cip-tramadol ER to treat moderate to moderately severe chronic pain
Dendreon Corp. (NASDAQ:DNDN) FDA approves Provenge sipuleucel-T to treat metastatic castrate-resistant prostate cancer
Genmab A/S (CSE:GEN)/ EC grants conditional approval for Arzerra ofatumumab to treat chronic lymphocytic
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)

Read the full 1698 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers